Fig. 8.

Effect of ROS generation and Bcl-2 expression on cisplatin-induced apoptosis. a HFDPC and HaCaT cells were treated with various concentrations of cisplatin (0–100 µM) for 24 h, and analyzed for apoptosis by Hoechst 33342 assay. b HFDPC and HaCaT cells were similarly treated with cisplatin and analyzed for ROS generation by flow cytometry at 2 h post-treatment. c HaCaT cells were transiently transfected with Bcl-2 or control pcDNA3 plasmid as described under “Material and methods” section. Transfected cells were analyzed for Bcl-2 expression by western blotting. d Transfected cells were treated with cisplatin (0–50 µM) for 24 h and analyzed for apoptosis by Hoechst 33342 assay. e Transfected cells were similarly treated with cisplatin and analyzed for ROS generation by flow cytometry at 2 h after the treatment. f Transfected cells were treated with ferrous sulfate (FeSO₄, 100 µM) and ROS generation was similarly determined after 2 h. Plots are mean ± SD (n = 3). *P < 0.05 versus non-treated control. P < 0.05 versus cisplatin-treated HFDPC cells. #P < 0.05 versus cisplatin-treated vector-transfected HaCaT cells